

1 **IL-6 trans-signaling mediates cytokine secretion and barrier dysfunction in**
2 **hantavirus infected cells and correlate to severity in HFRS**

3

4 Kimia T. Maleki^{a,e}, Linda Niemetz^{a,b,e}, Wanda Christ^a, Julia Wigren Byström^c, Therese
5 Thunberg^c, Clas Ahlm^c, Jonas Klingström^{a,d,*}

6

7 **Affiliations:**

8 ^aCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet,
9 Stockholm, Sweden.

10 ^bBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.

11 ^cDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.

12 ^dDivision of Molecular Medicine and Virology, Department of Biomedical and Clinical
13 Sciences, Linköping University, Linköping, Sweden.

14

15 ^e Both authors contributed equally.

16

17 *Corresponding author. Division of Molecular Medicine and Virology, Department of
18 Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.

19 *E-mail address:* Jonas.Klingstrom@liu.se (J. Klingström)

20

21 **Keywords:** IL-6 trans-signaling; IL-6; prognostic biomarkers; Hantavirus; Hemorrhagic fever
22 with renal syndrome (HFRS); Endothelial cells; Vascular permeability; Inflammation

23 **Abstract**

24 **Background:** Hantavirus causes hemorrhagic fever with renal syndrome (HFRS) and hantavirus
25 pulmonary syndrome (HPS). Strong inflammatory responses and vascular leakage are important
26 hallmarks of these often fatal diseases. The mechanism behind pathogenesis is unknown and no
27 specific treatment is available. IL-6 was recently highlighted as a biomarker for HPS/HFRS
28 severity. IL-6 signaling is complex and context dependent: while classical signaling generally
29 provide protective responses, trans-signaling can cause severe pathogenic responses. This study
30 aims to investigate a potential role for IL-6 trans-signaling in hantavirus pathogenesis.

31 **Methods:** Effects of IL-6 trans-signaling during *in vitro* hantavirus infection were assessed using
32 primary human endothelial cells treated with recombinant soluble IL-6 receptor (sIL-6R). Plasma
33 from Puumala orthohantavirus-infected HFRS patients (n=28) were analyzed for IL-6 trans-
34 signaling potential and its associations to severity.

35 **Findings:** *In vitro*, sIL-6R treatment of infected cells enhanced IL-6 and CCL2 secretion,
36 upregulated ICAM-1, and affected VE-cadherin leading to a disrupted cell barrier integrity.
37 HFRS patients showed altered plasma levels of sIL-6R and soluble gp130 (sgp130) resulting in
38 an increased sIL-6R/sgp130 ratio suggesting enhanced IL-6 trans-signaling potential. Plasma
39 sgp130 levels negatively correlated with number of interventions and positively with albumin
40 levels. Patients receiving oxygen treatment displayed a higher sIL-6R/sgp130 ratio compared to
41 patients that did not.

42 **Interpretation:** IL-6 trans-signaling is linked to hantavirus pathogenesis. Targeting IL-6 trans-
43 signaling might provide a therapeutic strategy for treatment of HPS and severe HFRS.

44 **Research in context**

45 **Evidence before this study**

46 IL-6 have dual effects, it provides important antiviral responses but can also cause severe
47 pathogenesis. IL-6 mediated effects are activated by two different mechanisms, classical
48 signaling and trans-signaling. IL-6 trans-signaling have recently been shown to be responsible
49 for IL-6 mediated pathogenesis. Endothelial cells lack membrane-bound IL-6 receptor and only
50 respond to IL-6 trans-signaling. Orthohantaviruses cause hemorrhagic fever with renal syndrome
51 (HFRS) and hantavirus pulmonary syndrome (HPS; also called hantavirus cardiopulmonary
52 syndrome (HCPS)), acute severe zoonotic diseases with high fatality rates for which specific
53 treatments and vaccines are lacking. Deregulated vascular permeability and inflammation are
54 hallmarks of HPS and severe HFRS. However, the mechanisms underlying hantavirus disease
55 are unknown, hampering the development of treatments. Orthohantaviruses primarily infect
56 endothelial cells. Previous studies have demonstrated a correlation between elevated IL-6 levels
57 and increased severity of HPS and HFRS. Whether this link is causal, and if so the mechanisms
58 behind it, has not been determined.

59

60 **Added value of this study**

61 This study demonstrates that hantavirus-infected endothelial cells produce large amounts of IL-6,
62 and are highly sensitive to IL-6 trans-signaling mechanisms. Together this strongly amplifies the
63 IL-6 production and disrupt the endothelial cell barrier causing severe fluid leakage. When
64 analyzing a potential role for IL-6 trans-signaling in patients, we observed increased systemic IL-
65 6 trans-signaling potential, and that this was linked to severity, in Puumala virus-infected HFRS
66 patients.

67 **Implications of all the available evidence**

68 These data suggest the two hallmarks of HPS and HFRS; increased vascular permeability and
69 strong inflammation, is linked via hantavirus-induced endothelial cell IL-6 production and IL-6
70 trans-signaling effects. Treatment targeting IL-6 trans-signaling might provide a therapeutic
71 strategy for HPS and severe HFRS.

72 INTRODUCTION

73 Orthohantavirus comprise a genus of single-stranded negative sense RNA viruses.¹
74 Orthohantaviruses, hereafter referred to as hantaviruses, are transmitted to humans via inhalation
75 of aerosolized virions from rodent excreta. Puumala orthohantavirus (PUUV) is the most
76 prevalent hantavirus species in Europe and causes hemorrhagic fever with renal syndrome
77 (HFRS).² HFRS patients typically present with headache, fever, myalgia and renal symptoms.^{2,3}
78 Fatality rates ranges between 0·4 to around 10%, depending on the specific hantavirus.^{2,3} In the
79 Americas, hantaviruses such as Andes virus (ANDV) cause hantavirus pulmonary syndrome
80 (HPS), a disease characterized by influenza-like symptoms and severe pulmonary dysfunction
81 leading to a fatality rate of around 30-40%.³ Lung involvement is also seen in many PUUV-
82 infected HFRS patients.⁴ Hantavirus primarily infects endothelial cells, especially in the lungs.²
83 Increased vascular permeability is a prominent hallmark of hantavirus infection, responsible for
84 the life-threatening pulmonary dysfunction in HPS and severe HFRS.² However, the mechanisms
85 behind hantavirus-induced vascular permeability are not known. As hantavirus infected cells are
86 protected from apoptosis,^{5,6} it is likely that other factors than endothelial cell death are involved
87 in the etiology of vascular permeability during hantavirus infection.^{2,3}

88 HFRS and HPS patients commonly exhibit increased systemic levels of pro-inflammatory
89 cytokines.⁷⁻¹¹ Recently, we and others reported that IL-6 is associated with increased disease
90 severity in HPS.^{7,12} In addition, we showed that serum IL-6 levels are higher in fatal compared to
91 non-fatal HPS cases.⁷ In PUUV-caused HFRS, high plasma IL-6 levels have been associated
92 with high serum creatinine levels, thrombocytopenia and longer hospitalization, suggesting that
93 IL-6 is associated also to the disease severity of HFRS.¹³ The mechanisms behind the association
94 between IL-6 and disease severity of hantavirus infections are currently unknown.

95 IL-6 is a pro-inflammatory cytokine with many functions including in eliciting the acute
96 phase response and promoting T cell activation and B cell maturation.¹⁴ IL-6 signals via a
97 receptor complex constituting of the IL-6 receptor (IL-6R) and gp130.^{14,15} Classical IL-6
98 signaling is achieved upon binding of IL-6 to membrane bound IL-6R and gp130.^{14,15} While
99 gp130 is expressed by all cells, IL-6R is expressed mainly by certain immune cells and
100 hepatocytes. Thus, classical IL-6 signaling is restricted only to these IL-6R-expressing cell
101 types.^{14,15} However, proteolytic cleavage and alternative splicing create soluble IL-6R (sIL-6R)
102 which binds to IL-6 with low affinity.¹⁶ In turn, the soluble IL-6:sIL-6R complex can bind to
103 gp130 on any cell and allow for so called IL-6 trans-signaling.^{15,17} Hence, trans-signaling allows
104 for IL-6 signaling in cells with low or absent IL-6R expression. Recently, it has become evident
105 that trans-signaling is the predominant pathway behind IL-6 mediated pathogenesis.¹⁸ Also
106 gp130 exists as a soluble version, soluble gp130 (sgp130), produced by proteolytic cleavage as
107 well as alternative splicing.¹⁹ sgp130 can bind to the IL-6:sIL-6R complex, hindering binding to
108 membrane bound gp130, thereby inhibiting trans-signaling.¹⁹ In blood, sIL-6 and sgp130 levels
109 are high, and their ratio will determine the IL-6 trans-signaling potential, thereby affecting the
110 potential pathogenic effects of IL-6 in circulation.¹⁸

111 Endothelial cells can produce high levels of IL-6 upon stimulation.²⁰ As endothelial cells
112 express no or very little IL-6R, they *per se* do not seem to respond to the IL-6 they produce.²⁰⁻²³
113 However, studies have shown that addition of sIL-6R to endothelial cell cultures renders them
114 responsive to IL-6 via trans-signaling.²¹

115 Here, we sought to investigate the source of IL-6 during hantavirus infection, as well as
116 the possible consequences of IL-6 trans-signaling on infected vascular endothelial cells. We
117 show that endothelial cells produce large amounts of IL-6 upon PUUV infection. Addition of

118 sIL-6R to PUUV infected endothelial cells lead to strongly enhanced secretion of IL-6 and CCL2
119 and upregulation of ICAM-1 on the cell surface. In addition, we show that sIL-6R led to VE-
120 cadherin internalization and increased monolayer permeability in infected endothelial cells.
121 Finally, we show that HFRS patients exhibit altered levels of sIL-6R and sgp130, and that this
122 correlate to markers of severity, suggesting a direct role for IL-6, via IL-6 trans-signaling, in
123 hantavirus pathogenesis.

124 **METHODS**

125 **Patients**

126 Twenty-eight HFRS patients were included in the study. Patients were diagnosed during the
127 years 2006-2014, at the University Hospital of Umeå, Sweden. Twenty uninfected controls
128 sampled in 2017 were included as control subjects. Peripheral blood was collected into CPT
129 tubes, as described previously.²⁴ Following centrifugation, plasma was retrieved and stored at
130 -80°C until analysis. All subjects provided written consent before participation in the study.
131 Ethical approval was obtained from the Regional Ethics Committee of Umeå University
132 (application number 04-133M).

133 The HFRS cohort included 13 females and 15 males with a mean age of 49 years (range
134 18-78 years) and the controls included 7 females and 13 males of a mean age of 50 years (range
135 37-63 years) (Table 1). Samples were collected from the acute phase at a median of 5 days
136 (range 2-7 days) post symptom debut, and from the convalescent phase at a median of 98 days
137 (range 42-494 days) post symptom debut (Table 1).

138

139 **Cells and viruses**

140 Pooled human umbilical vein endothelial cells (HUVECs) (Lonza) were maintained in
141 endothelial growth medium (EGM-2) supplemented with EGM-2 endothelial SingleQuots
142 (Lonza) in 5% CO₂ at 37°C. Prior to experiments, hydrocortisone was excluded from the
143 medium. Buffy coats from blood donors were purchased from Karolinska University Hospital
144 (Stockholm, Sweden). Peripheral blood mononuclear cells (PBMCs) were isolated from buffy
145 coats using Lymphoprep (Stemcell Technologies) and maintained in RPMI-1640 medium (GE
146 Healthcare) supplemented with 10% FCS (Sigma-Aldrich) and 2 mM L-glutamine (Life

147 Technologies). PUUV strain CG1820 was propagated on A549 cells and ANDV strain Chile-
148 9717869 on Vero E6 cells, as previously described.²⁵

149

150 **Infection and treatments**

151 HUVECs were infected with 200 µl (in 24 well plates) or 1 ml (in 6 well plates) virus diluted in
152 HUVEC medium at multiplicity of infection (MOI) 1. Cells were infected for 1 h in 5% CO₂ at
153 37°C, with gentle shaking every 10 min. After infection, virus was removed and replaced with 1
154 ml fresh medium. At 48 h post infection, medium was replaced with medium containing
155 recombinant human IL-6R alpha protein (R&D systems) at different concentrations. Cells
156 without sIL-6R treatment and cells treated with 10 ng/ml recombinant IL-6 (rIL-6) (R&D
157 systems), in addition to the sIL-6R treatment, were used as controls. After 24 h treatment,
158 supernatants were collected and stored at -80°C until analysis.

159 PBMCs cultured in 96-well plates (1 million cells in 200 µl medium) were exposed to
160 PUUV (MOI=3) for 2 h in 5% CO₂ at 37°C. After infection, virus was removed and replaced
161 with fresh medium. Supernatants were collected after a centrifugation step and stored at -80°C
162 until analysis.

163

164 **Flow cytometric analyses**

165 HUVECs were detached using Accutase (Thermo Fisher Scientific) and then used for flow
166 cytometry. HUVECs were stained with anti-ICAM-1 antibody conjugated with PE-Vio770
167 (Milteny Biotec) for 20 min at room temperature (RT). Live/Dead Aqua (Invitrogen) was used
168 for the identification of dead cells. Cells were fixed for 30 min using Transcription Factor

169 Staining Buffer Set (BD Biosciences). Samples were acquired on a BD LSR Fortessa instrument
170 (BD Biosciences). Data were analyzed using FlowJo version 10.4.

171

172 **ELISA**

173 Prior to ELISA, plasma samples were diluted in ready-to-use ELISA diluent (Mabtech); 1:2 for
174 IL-6 and IL-6/sIL-6R complex and 1:400 for sIL-6R and sgp130 ELISAs. Levels of IL-6 were
175 analyzed using ELISA development kit (Mabtech) and levels of sIL-6R, IL-6:IL-6R complex,
176 and sgp130 were analyzed using DuoSet ELISA kits (R&D), all according to the manufacturer's
177 guidelines.

178

179 **Immunofluorescence**

180 HUVECs cultured on glass cover slips were fixed with pre-warmed 4% paraformaldehyde for 15
181 min at RT. Cells were then permeabilized using 0.5% Triton X for 5 min at RT, washed three
182 times and blocked with 0.5% BSA in PBS for 30 min at RT. Cover slips were incubated with
183 primary antibody for 1 h at RT, washed in PBS three times and then incubated with secondary
184 antibody for 1 h at RT. VE-cadherin expression was detected using anti-VE-cadherin
185 monoclonal antibody (Cell Signaling Technology) and goat anti-rabbit IgG AF488 (Life
186 Technologies). PUUV proteins were detected using polyclonal antibodies from convalescent
187 patient serum for 1 h at RT and goat anti-human IgG AF647 (Life Technologies). Nuclei were
188 stained using DAPI (Life Technologies). Washed cover slips were mounted onto glass slides
189 using ProLong Gold Antifade Mountant (Thermo Fisher Scientific). Cells were examined by
190 immunofluorescence confocal microscopy at 60X magnification. Images were analyzed using
191 ImageJ.

192 **Transendothelial electrical resistance (TEER)**

193 HUVECs, uninfected or infected with PUUV for 24 h, were split onto HTS Transwell 24-well
194 plates with 0.4 µm pore and 6.5 mm inserts (Corning) at a density of 1×10^5 cells in 100 µl per
195 well. To the lower compartment, 600 µl medium was added. Cells were cultured at 37°C for 24 h
196 and then treated with sIL-6R. The transendothelial electrical resistance (TEER) was measured
197 after 24 h using an EVOM2 epithelial voltohmmeter (World precision instruments), according to
198 the manufacturer's guidelines. The mean TEER of three measurements/well was used to
199 calculate the TEER/cm².

200


201 **Statistical analyses**

202 Statistical analyses were performed using Graph Pad Prism v.9. Paired comparisons within
203 HFRS patients were performed using Wilcoxon test. Comparisons between controls and acute
204 and convalescent HFRS patients were performed using Kruskal-Wallis test followed by Dunn's
205 multiple comparison test. Comparisons between *in vitro* conditions were performed using two-
206 way ANOVA followed by Dunnet's or Šidák's multiple comparison test. Spearman's rank
207 correlation coefficient was used for examining correlations.

208 **RESULTS**

209 **PUUV-infected cells demonstrate potent IL-6 secretion**

210 To investigate possible sources of IL-6 production during hantavirus infection, we assessed IL-6
211 secretion from HUVECs and PBMCs. HUVECs were infected with PUUV at MOI 1 and
212 supernatants were collected at 24, 48, and 72 h post infection. Infected HUVECs produced
213 higher levels of IL-6 than uninfected HUVECs at 48 and 72 h post infection (Figure 1A).
214 PBMCs were exposed to PUUV at MOI 3 and supernatants were collected after 24, 48, and 72 h.
215 At 48 h post PUUV-exposure, PBMCs produced higher levels of IL-6 compared to unexposed
216 PBMCs, albeit at lower concentrations than HUVECs (Figure 1B). Next, we examined the
217 concentrations of sgp130 in the supernatants. In infected HUVECs, the levels of sgp130 were
218 significantly increased at 72 h post infection (Figure 1C). In supernatants of PUUV-exposed
219 PBMCs, no such increase was observed (Figure 1D). In the PBMC supernatants, also sIL-6R
220 levels were analyzed. No significant increase in sIL-6R levels was observed in PUUV-exposed
221 compared to unexposed PBMCs (Figure 1D). Together, these data show that PUUV induces
222 strong IL-6 secretion in HUVECs and PBMCs, and that this coincides with increased production
223 of sgp130 in HUVECs.




224
 225 **Fig. 1. PUUV-infected cells secrete IL-6.** HUVECs were infected with PUUV (MOI=1) and
 226 PBMCs were exposed to PUUV (MOI=3) for 24-72 h. Supernatants were assessed for IL-6,
 227 soluble gp130 (sgp130), and soluble IL-6R (sIL-6R) using ELISA. (A) Levels of IL-6 in
 228 supernatants of HUVECs (n=3) and (B) PBMCs (24-48 h, n=6, 72 h, n=2). (C) sgp130 levels in
 229 supernatants of HUVECs (n=3). (D) Levels of sgp130 (n=2) and sIL-6R (n=7) in PBMC
 230 supernatants. Two-way ANOVA followed by Šídák's multiple comparison test. *, $p < 0.05$, **,
 231 $p < 0.01$.

232
 233 **IL-6 trans-signaling in PUUV-infected cells drives inflammation**
 234 Having shown that HUVECs produce high levels of IL-6 upon PUUV infection, we next
 235 investigated potential autocrine effects of IL-6 trans-signaling on endothelial cells. IL-6 trans-
 236 signaling in endothelial cells has been shown to increase secretion of IL-6,²¹ and CCL2.^{22,24} As

237 endothelial cells have been reported to be unresponsive to IL-6 treatment,²¹ inflammatory
238 responses downstream of IL-6 were assessed after addition of recombinant sIL-6R to the cell
239 cultures. At 48 h post infection, HUVEC medium was exchanged to fresh medium with or
240 without different concentrations of sIL-6R. After 24 h of treatment, IL-6 and CCL2 levels in
241 supernatants were determined by ELISA. Levels of IL-6 and CCL2 in supernatants were
242 increased in infected HUVECs treated with sIL-6R, in a dose-dependent manner (Figure 2A-B).
243 As expected,^{22,26} increased CCL2 secretion was also observed in uninfected HUVECs treated
244 with recombinant IL-6 (rIL-6) along with the sIL-6R treatment (Figure S1A).

245 IL-6 signaling has been reported to increase the cell surface expression of ICAM-1 on
246 endothelial cells.²⁶⁻²⁹ Thus, ICAM-1 expression on HUVECs was assessed by flow cytometry.
247 As previously observed for Hantaan orthohantavirus (HTNV) infected cells,^{30,31} increased
248 ICAM-1 expression was observed on PUUV-infected compared to uninfected HUVECs (Figure
249 2C-D). Addition of sIL-6R to the cultures further increased the ICAM-1 expression on infected,
250 but not uninfected cells, in a dose-dependent manner (Figure 2C-D). Together, these data
251 indicate that endogenously produced IL-6 from PUUV-infected endothelial cells, in presence of
252 sIL-6R, stimulate IL-6 trans-signaling in an autocrine manner that fuels the inflammatory
253 responses by causing endothelial cell activation and increased secretion of IL-6 and CCL2.



254
 255 **Fig. 2. IL-6 trans-signaling activates endothelial cells and drives inflammation.** HUVECs
 256 were infected with PUUV (MOI=1) for 48 h and then treated with sIL-6R at the concentrations
 257 31.25, 62.5, 125, 250, or 500 ng/ml for 24 h or left untreated. (A) Levels of IL-6 (n=5) and (B)
 258 CCL2 (n=3) in supernatants of uninfected and PUUV-infected HUVECs. (C) Representative
 259 histogram plot and (D) graph showing median ICAM-1 expression on infected and uninfected
 260 HUVECs (n=3). Symbols depict mean and error bars indicate SD. Two-way ANOVA followed
 261 by Dunnet's or Šídák's multiple comparison test. Black asterisks indicate significance when
 262 comparing PUUV to uninfected. Red asterisks indicate significance when comparing each sIL-
 263 6R-treated conditions of PUUV-infected cells with untreated PUUV-infected cells. *, p<0.05;
 264 **, p<0.01; ***, p<0.001, ****, p<0.0001.

265

266 Levels of IL-6 in supernatants were also increased in ANDV-infected HUVECs treated
267 with sIL-6R (Figure S2), suggesting this is a common feature of HFRS and HPS-causing
268 hantaviruses.


269

270 **PUUV-mediated IL-6 trans-signaling disrupts endothelial cell barrier functions**

271 To further investigate the functional consequences of IL-6 trans-signaling, we sought to evaluate
272 the barrier function in infected HUVEC monolayers. For this purpose, we first examined the
273 expression of VE-cadherin in infected and uninfected cells, with or without sIL-6R, using
274 immunofluorescence microscopy. In uninfected untreated cells, solid VE-cadherin junctions and
275 intact cell monolayers were observed (Figure 3A). Addition of sIL-6R to uninfected cells had no
276 clear effect on the VE-cadherin organization nor the cell integrity (Figure 3A). In contrast,
277 internalization of VE-cadherin was seen in PUUV-infected HUVECs without sIL-6R treatment
278 (Figure 3A). sIL-6R treatment of infected cells caused further downmodulation of VE-cadherin
279 from the cell surface (Figure 3A). Interestingly, while the cell monolayer appeared to be intact in
280 untreated PUUV-infected cells, sIL-6R treatment caused gap formation in the cell monolayer,
281 indicating that the barrier function was severely disrupted (Figure 3A). As expected, a similar
282 phenotype was observed when uninfected cells were treated with rIL-6 in addition to the sIL-6R
283 treatment (Figure S1B), showing that this indeed was dependent on IL-6 trans-signaling.

284 To further examine the endothelial cell barrier function upon sIL-6R treatment, we
285 analyzed the transendothelial electrical resistance (TEER) in PUUV-infected and uninfected
286 HUVECs. PUUV infection alone caused decreased TEER compared to uninfected cells (Figure
287 3B). PUUV infection together with sIL-6R treatment further caused a dose-dependent loss of
288 barrier function 24 h post treatment, as indicated by decreased TEER compared to uninfected

289 HUVECs and PUUV-infected untreated cells (Figure 3B). Similarly, a dose-dependent decrease
290 in TEER was observed when uninfected cells were treated with rIL-6 + sIL-6R (Figure 3B).
291 Supporting previous reports,^{32,33} rIL-6 treatment alone did not affect the monolayer permeability
292 in uninfected HUVECs (Figure 3B). Collectively, these data indicate that IL-6 produced by
293 PUUV-infected endothelial cells in an IL-6 trans-signaling dependent manner enhances VE-
294 cadherin disorganization and loss of endothelial cell monolayer integrity.



295

296 **Fig. 3. IL-6 trans-signaling disrupts endothelial cell barrier functions during hantavirus**

297 **infection.** Uninfected and infected HUVECs were treated with sIL-6R at the concentrations

298 31.25, 62.5, 125, 250, or 500 ng/ml for 24 h or left untreated. (A) Immunofluorescence images

299 showing expression of DAPI (blue), virus (red), and VE-cadherin (green). Representative

300 images of three independent experiments are shown. (B) Transendothelial electrical resistance of


301 uninfected (white symbol) and infected HUVECs (black symbol), with and without sIL-6R.
302 Uninfected HUVECs treated with rIL-6 in addition to sIL-6R were used as control (grey
303 symbol). Symbols depict mean and error bars indicate SD. Two-way ANOVA followed by
304 Dunnet's or Šídák's multiple comparison test. Black asterisks indicate significance when
305 comparing PUUV to uninfected. Red asterisks indicate significance when comparing each sIL-
306 6R-treated conditions of PUUV-infected cells with untreated PUUV-infected cells. *, $p < 0.05$;
307 **, $p < 0.01$; ***, $p < 0.001$, ****, $p < 0.0001$.

308

309 **The plasma sIL-6R/gp130 ratio is increased during acute HFRS**

310 Given the pronounced effects of IL-6 trans-signaling observed in hantavirus infected cells *in*
311 *vitro*, we next sought to evaluate the levels of soluble IL-6 receptors in HFRS patients. The
312 physiological effects of IL-6 largely depend on the levels of sIL-6R and sgp130 in
313 circulation.^{15,18} Although increased systemic IL-6 levels have been repeatedly reported in HFRS
314 and HPS patients,^{7-9,11,12} the concentrations of sIL-6R and sgp130 have not yet been
315 comprehensively studied in hantavirus-infected patients. Thus, we analyzed the levels of IL-6,
316 sIL-6R, IL-6:sIL-6R complex, and sgp130 in plasma of 28 PUUV-infected HFRS patients,
317 during acute and convalescent phase, as well as in 20 uninfected controls. The HFRS patients
318 displayed typical symptoms for HFRS, showing thrombocytopenia, and elevated levels of
319 creatinine and CRP (Table 1). Information regarding complications (thrombosis, severe
320 bleeding) as well as information on medical interventions including administration of
321 intravenous fluid, oxygen treatment, and platelet transfusion are presented in Table 1. IL-6 levels
322 were, as previously reported,^{8,11} increased in acute HFRS (Figure 4A). Levels of sIL-6R were
323 higher during acute, compared to the convalescent, HFRS, and similar to that observed in

324 uninfected controls (Figure 4B). Levels of the IL-6:sIL-6R complex were not significantly
 325 altered during HFRS (Figure 4C) while sgp130 levels were decreased in both acute and
 326 convalescent HFRS, compared to controls (Figure 4D). sgp130 binds to the IL-6:sIL-6R complex
 327 thereby inhibiting binding of the complex to membrane bound gp130.¹⁷ Thus, when assessing the
 328 likelihood of IL-6 trans-signaling, the proportion of sIL-6R in relation to sgp130 is important to
 329 consider. To better assess the relation of the IL-6 receptors during HFRS, the ratio between sIL-
 330 6R and sgp130 was calculated. Interestingly, the sIL-6R/sgp130 ratio was significantly increased
 331 during acute HFRS, as compared to convalescent HFRS and controls (Figure 4E). Taken
 332 together, this suggests increased IL-6-trans-signaling potential during acute HFRS.
 333



334
 335 **Fig. 4. The plasma sIL-6R/sgp130 ratio is increased during acute HFRS and IL-6 trans-**
 336 **signaling potential correlate to severity.** Plasma levels of (A) IL-6, (B) sIL-6R, (C) IL-6:sIL-
 337 6R complex, and (D) sgp130 in controls (n=20) and acute and convalescent HFRS patients

338 (n=28). (E) Ratio of plasma sIL-6R and sgp130 in controls and HFERS patients (n=27). (F)
339 Correlation between sgp130 levels and number of interventions during acute HFERS (n=28). (G)
340 Correlation between sgp130 levels and serum albumin (n=13). (H) Plasma sIL-6R/sgp130 ratio
341 in patients with or without oxygen treatment (median, interquartile range). Wilcoxon test;
342 Kruskal-Wallis test; median. Spearman's rank correlation coefficient. *, $p < 0.05$; **, $p < 0.01$; ***,
343 $p < 0.001$, ****, $p < 0.0001$.

344

345 **Sgp130 level and IL-6 trans-signaling potential correlate to disease severity**

346 We finally analyzed for possible correlations of IL-6 signaling factors, including IL-6 trans-
347 signaling potential, and severity of HFERS. This revealed that sgp130 levels were inversely
348 correlated with the number of interventions in patients (Figure 4F), suggesting that patients with
349 a more complicated disease had the lowest sgp130 levels. Furthermore, sgp130 levels positively
350 correlated with serum albumin levels (Figure 4G), indicating that decreased sgp130 levels
351 coincide with loss of serum albumin, which is indicative of increased vascular permeability. The
352 sIL-6R/sgp130 ratio was significantly higher in patients receiving oxygen treatment (Figure 4H).
353 Together, this suggest low sgp130 levels and high IL-6 trans-signaling potential is associated
354 with severe HFERS.

355 **DISCUSSION**

356 HFRS and HPS are characterized by strong inflammatory responses and vascular
357 permeability.^{2,3,7-11} Despite significant morbidity and mortality in hantavirus-infected
358 individuals, no specific treatments are available. Importantly, the mechanisms driving
359 hantavirus-mediated pathogenesis are not known, hampering development of specific
360 therapeutics. IL-6 has been highlighted as an important cytokine in hantavirus infections, as it is
361 associated with HFRS and HPS disease severity.^{7,12,13} However, the potential role for IL-6 in the
362 pathophysiology of hantavirus diseases is unknown. Here, we report IL-6 trans-signaling as a
363 potential mechanism behind IL-6-mediated pathology during hantavirus infections.

364 We observed that PUUV infection stimulates IL-6 secretion in HUVECs and PBMCs. IL-
365 6 secretion has previously been reported in cells infected with ANDV, HTNV, and Prospect Hill
366 orthohantavirus.^{34,35} When studying IL-6 signaling *in vitro*, it is important to consider the
367 receptor availability on the cells of the model system. While gp130 is expressed by all cells, IL-
368 6R is mainly expressed by hepatocytes and certain immune cells.¹⁴ Endothelial cells express no
369 or very little IL-6R, and therefore display no or limited responses to IL-6 *per se*.^{20,21,36} This may
370 explain why a previous study did not observe any effect upon IL-6 treatment of hantavirus
371 infected cells.³² However, treatment of endothelial cells with IL-6 in combination with sIL-6R
372 leads to IL-6 trans-signaling. IL-6 trans-signaling in endothelial cells has been shown to cause
373 secretion of IL-6 and CCL2 as well as upregulation of ICAM-1 on the cell surface.^{21,22,26-29} Here,
374 we recapitulated these findings in a PUUV-infection model. Using this model, we showed that
375 PUUV-induced endogenous IL-6, in presence of sIL-6R, activated endothelial cells in an
376 autocrine manner. This activation caused upregulation of the adhesion molecule ICAM-1,
377 indicating enhanced activation of the endothelial cells. This is in line with the increased plasma
378 levels of soluble ICAM-1, VCAM-1, E-selectin, and syndecan-1 observed in HFRS patients.³⁷

379 PUUV-mediated IL-6 trans-signaling further promoted a pro-inflammatory loop with augmented
380 secretion of IL-6 and CCL2. CCL2 is a known chemoattractant for T cells and myeloid cells.^{38,39}
381 Apart from its chemoattracting function, CCL2 also mediates attachment to vascular endothelial
382 cells and trans-endothelial migration of T cells and myeloid cells.³⁸⁻⁴⁰ Together, these data
383 suggest that infected endothelial cells may, via IL-6 trans-signaling, constitute important drivers
384 of IL-6 production and inflammation in HFRS/HPS patients.

385 Vascular permeability is a common hallmark of hantavirus infections.^{2,3} The mechanism
386 behind why hantavirus infection leads to massively increased vascular permeability, including
387 the life-threatening pulmonary dysfunction observed in HPS, is largely unknown.³ Here, we
388 demonstrated that sIL-6R treatment of infected endothelial cells increases VE-cadherin
389 disorganization and barrier permeability. This is in line with previous reports showing VE-
390 cadherin internalization and increased permeability of endothelial cells treated with IL-6 in
391 combination with sIL-6R.^{28,33,41} Remarkably, PUUV infection alone, without sIL-6R treatment,
392 caused some VE-cadherin internalization and decreased monolayer integrity. Previously, a
393 VEGF/VEGFR2-dependent internalization of VE-cadherin has been described in ANDV and
394 HTNV infected endothelial cells.^{42,43} Such a VEGF-dependent mechanism could possibly
395 explain the VE-cadherin disorganization and decreased membrane integrity seen in untreated
396 PUUV-infected HUVECs. Taken together, these findings indicate that hantavirus infection alone
397 to some extent modulates the endothelial cell barrier integrity, and that subsequent IL-6 trans-
398 signaling further aggravates this, leading to a severe loss of barrier function.

399 The *in vivo* effects of IL-6 depend on the complex interactions of IL-6 with sIL-6R and
400 sgp130, which constitute a buffer system that regulates the half-life and signaling of IL-6.^{15,18}
401 While it is well-established that IL-6 levels are increased in HFRS and HPS patients, peripheral

402 levels of sIL-6R and sgp130 have not been extensively studied in hantavirus infected patients.
403 Here, plasma sIL-6R levels were found to be elevated during the acute, compared to the
404 convalescent, phase of HFRS. Intriguingly, compared to controls, lower plasma sgp130
405 concentration was observed both during acute and convalescent HFRS. As sgp130 can inhibit IL-
406 6 trans-signaling,¹⁹ a decrease in sgp130 may have pathogenic consequences. In support of this
407 notion, decreased sgp130 levels have been described in patients with type 2-diabetes,⁴⁴ and in
408 patients with coronary artery disease.⁴⁵⁻⁴⁷ Furthermore, increased sgp130 levels have been
409 associated with decreased odds of myocardial infarction.⁴⁸ The inverse correlation found
410 between plasma sgp130 and number of interventions during acute HFRS may indicate that
411 patients with low sgp130 levels also have more severe symptoms. Albumin has been suggested
412 as a marker of vascular permeability.⁴⁹ Thus, the positive correlation between sgp130 levels and
413 serum albumin levels during acute HFRS may suggest a link between low sgp130 levels and
414 increased vascular leakage. Interestingly, in patients with coronavirus disease 2019 (COVID-19),
415 low levels of serum albumin have been associated with more severe pulmonary symptoms.⁵⁰
416 Analyses of IL-6 receptor levels and of possible correlations to risk for severe and fatal outcome
417 in HPS patients could help decipher the role of IL-6 trans-signaling in hantavirus-induced
418 pathogenesis, as these patients in general are more severely ill than HFRS patients.

419 The skewed IL-6-receptor balance during acute HFRS, as indicated by the increased sIL-
420 6R/sgp130 ratio, suggests an increased potential of IL-6-trans-signaling in patients. Importantly,
421 while classical signaling via membrane-bound IL-6R mainly seems to have homeostatic,
422 protective, effects, trans-signaling has recently emerged as the driver of IL-6 mediated
423 pathogenesis.¹⁸ In most HFRS patients, plasma IL-6 levels are not as strongly elevated as
424 observed in HPS patients. Given the capacity of endothelial cells to produce large amounts of IL-

425 6, it is possible that the concentration of IL-6 is higher at local sites of infection than
426 systemically. It is further possible that highly vascularized sites, such as the lungs, have very
427 high local concentrations of infected endothelial cell-derived IL-6, and as a consequence are
428 more exposed to IL-6 trans-signaling. This scenario is consistent with the observations that lungs
429 are heavily affected during HPS, and that almost all lung endothelial cells are infected in some
430 patients.⁵¹⁻⁵³ Altogether, our data suggest altered concentrations of sIL-6R and sgp130 during
431 hantavirus-infection, which may increase the likelihood of IL-6 trans-signaling in infected
432 endothelial cells and increased vascular permeability as a consequence.

433 Treatment strategies targeting IL-6 signaling have proven successful in for example
434 rheumatoid arthritis and for treatment of COVID-19.^{18,54,55} Further studies investigating the role
435 of IL-6 in the pathogenesis of HFRS and HPS will be valuable for the assessment of the
436 relevance of IL-6-targeting therapeutics in severe hantavirus infections. In conclusion, we show
437 that PUUV-infected endothelial cells produce IL-6 that, in an IL-6 trans-signaling dependent
438 manner, strongly affect infected endothelial cell functions. We further show a correlation
439 between IL-6 trans-signaling potential and severity in HFRS patients. These findings suggest that
440 IL-6 trans-signaling may represent a treatable target in HPS and severe HFRS.

441 **Data sharing**

442 All data are available in the main text or the supplementary materials.

443

444 **Acknowledgements**

445 We thank the patients and volunteers who contributed with clinical material to this study. C.

446 Ahlm received fundings from Region Västerbotten and Umeå University, project numbers RV-

447 579011, RV-734361, and RV-965866, and from the Heart-Lung Foundation, project numbers

448 20170334 and 20150752. J. Klingström received fundings from the Swedish Research Council,

449 project number 2018-02646, and from the center for medical innovation (CIMED), project

450 number 2020-0141.

451 The funders played no role in the design of the study, data collection, data analysis, interpretation

452 of results or writing of the paper.

453

454 **Declaration of interests**

455 Authors declare that they have no competing interests.

456

457 **Author contributions**

458 Conceptualization: KTM, JK

459 Methodology: KTM, LN, WC, JK

460 Investigation: KTM, LN, WC, TT, CA

461 Analyzed data: KTM

462 Validated data: KTM, LN

463 Visualization: KTM

464 Funding acquisition: CA, JK

465 Project Administration: KTM, JK

466 Resources: JWB, TT, CA

467 Supervision: KTM, JK

468 Writing – original draft: KTM, JK

469 Writing – review & editing: KTM, LN, WC, JWB, TT, CA, JK

470 References

- 471 1 Bradfute SB, Calisher CH, Klempa B, Klingström J, Kuhn JH, Laenen L, et al. ICTV virus
472 taxonomy profile: Hantaviridae 2024. *J Gen Virol.* 2024;105:001975.
473
- 474 2 Klingström J, Smed-Sörensen A, Maleki KT, Solà-Riera C, Ahlm C, Björkström NK, et
475 al. Innate and adaptive immune responses against human Puumala virus infection:
476 immunopathogenesis and suggestions for novel treatment strategies for severe hantavirus-
477 associated syndromes. *J Inter. Med.* 2019;285:510–523.
478
- 479 3 Vial PA, Ferrés M, Vial C, Klingström J, Ahlm C, López R, et al. Hantavirus in humans:
480 a review of clinical aspects and management. *Lancet Infect Dis.* 2023;23:e371–e382.
481
- 482 4 Rasmuson J, Lindqvist P, Sörensen K, Hedström H, Blomberg A, Ahlm C.
483 Cardiopulmonary involvement in Puumala hantavirus infection. *BMC Infect Dis.* 2013;13:501.
484
- 485 5 Solà-Riera C, Gupta S, Ljunggren H-G, Klingström J. Orthohantaviruses belonging to
486 three phylogroups all inhibit apoptosis in infected target cells. *Sci Rep.* 2019;9:834.
487
- 488 6 Solà-Riera C, García M, Ljunggren H-G, Klingström J. Hantavirus inhibits apoptosis by
489 preventing mitochondrial membrane potential loss through up-regulation of the pro-survival factor
490 BCL-2. *PLoS Pathog.* 2020;16:e1008297.
491
- 492 7 Maleki KT, García M, Iglesias A, Alonso D, Ciancaglini M, Hammar U, et al. Serum
493 markers associated with severity and outcome of hantavirus pulmonary syndrome. *J Infect Dis.*
494 2019;219:1832–1840.
495
- 496 8 Linderholm M, Ahlm C, Settergren B, Waage A., Tärnvik A. Elevated plasma levels of
497 tumor necrosis factor (TNF)-alpha, soluble TNF receptors, interleukin (IL)-6, and IL-10 in patients
498 with hemorrhagic fever with renal syndrome. *J Infect Dis.* 1996;173:38–43.
499
- 500 9 Morzunov SP, Khaiboullina SF, St Jeor S, Rizvanov AA, Lombardi VC. Multiplex analysis
501 of serum cytokines in humans with hantavirus pulmonary syndrome. *Front Immunol.* 2015;6:432.
502
- 503 10 Saksida A, Wraber B, Avšič-Županc T. Serum levels of inflammatory and regulatory
504 cytokines in patients with hemorrhagic fever with renal syndrome. *BMC Infect Dis.* 2011;11:142.
505
- 506 11 Sadeghi M, Eckerle I, Daniel V, Burkhardt U, Opelz G, Schnitzler P. Cytokine expression
507 during early and late phase of acute Puumala hantavirus infection. *BMC Immunol.* 2011;12:65.
508
- 509 12 Angulo J, Martínez-Valdebenito C, Marco C, Galeno H, Villagra E, Vera L et al. Serum
510 levels of interleukin-6 are linked to the severity of the disease caused by Andes Virus. *PLoS Negl*
511 *Trop Dis.* 2017;11:e0005757.
512

- 513 13 Outinen TK, Mäkelä SM, Ala-Houhala IO, Huhtala HS, Hurme M, Paakkala AS, et al. The
514 severity of Puumala hantavirus induced nephropathia epidemica can be better evaluated using
515 plasma interleukin-6 than C-reactive protein determinations. *BMC Infect Dis.* 2010;10:132.
516
- 517 14 Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. *Nat Immunol.*
518 2015;16:448–457.
519
- 520 15 Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-
521 inflammatory activities of IL-6. *Int. J Biol Sci.* 2012;8:1237–1247.
522
- 523 16 Mülberg J, Schooltink H, Stoyan T, Günther M, Graeve L, Buse G, et al. The soluble
524 interleukin-6 receptor is generated by shedding. *Eur J Immunol.* 1993;23:473–480.
525
- 526 17 Baran P, Hansen S, Waetzig GH, Akbarzadeh M, Lamertz L, Huber HJ, et al. The balance
527 of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes
528 allows simultaneous classic and trans-signaling. *J Biol Chem.* 2018;293:6762–6775.
529
- 530 18 Rose-John S, Jenkins BJ, Garbers C, Moll JM, Scheller T. Targeting IL-6 trans-signalling:
531 past, present and future prospects. *Nat Rev Immunol.* 2023;23:666–681.
532
- 533 19 Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y, et al. Soluble forms
534 of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a
535 potential to inhibit signals through membrane-anchored gp130. *Blood* 1993;82:1120–1126.
536
- 537 20 Podor TJ, Jirik FR, Loskutoff DJ, Carson DA, Lotz M. Human endothelial cells produce
538 IL-6. Lack of responses to exogenous IL-6. *Ann N Y Acad Sci.* 1989;557:374–387.
539
- 540 21 Modur V, Li Y, Zimmerman GA, Prescott SM, McIntyre TM. Retrograde inflammatory
541 signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. *J Clin*
542 *Invest.* 1997;100:2752–2756.
543
- 544 22 Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, et al. Role of IL-6
545 and its soluble receptor in induction of chemokines and leukocyte recruitment. *Immunity*
546 1997;6:315–325.
547
- 548 23 Montgomery A, Tam F, Gursche C, Cheneval C, Besler K, Enns W, et al. Overlapping and
549 distinct biological effects of IL-6 classic and trans-signaling in vascular endothelial cells. *Am J*
550 *Physiol Cell Physiol.* 2021;320:C554–C565.
- 551 24 Scholz S, Baharom F, Rankin G, Maleki KT, Gupta S, et al. Human hantavirus infection
552 elicits pronounced redistribution of mononuclear phagocytes in peripheral blood and airways.
553 *PLoS Pathog.* 2017;13:e1006462.
554
- 555 25 Stoltz M, Ahlm C, Lundkvist Å, Klingström J. Lambda interferon (IFN-lambda) in serum
556 is decreased in hantavirus-infected patients, and in vitro-established infection is insensitive to
557 treatment with all IFNs and inhibits IFN-gamma-induced nitric oxide production. *J Virol.*
558 2007;81:8685–8691.

- 559 26 Suzuki M, Hashizume M, Yoshida H, Mihara M. Anti-inflammatory mechanism of
560 tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and
561 adhesion molecule. *Rheumatol Int.* 2009;30:309.
562
- 563 27 Watson C, Whittaker S, Smith N, Vora AJ, Dumonde DC, Brown KA. IL-6 acts on
564 endothelial cells to preferentially increase their adherence for lymphocytes. *Clin Exp Immunol.*
565 1996;105:112–119.
566
- 567 28 Valle ML, Dworshak J, Sharma A, Ibrahim AS, Al-Shabrawey M, Sharma S. Inhibition of
568 interleukin-6 trans-signaling prevents inflammation and endothelial barrier disruption in retinal
569 endothelial cells. *Exp Eye Res.* 2019;178:27–36.
570
- 571 29 Wung BS, Ni CW, Wang DL. ICAM-1 induction by TNFalpha and IL-6 is mediated by
572 distinct pathways via Rac in endothelial cells. *J Biomed Sci.* 2005;12:91–101.
573
- 574 30 Björkström NK, Lindgren T, Stoltz M, Fauriat C, Braun M, Evander M, et al. Rapid
575 expansion and long-term persistence of elevated NK cell numbers in humans infected with
576 hantavirus. *J Exp Med.* 2011;208:13–21.
577
- 578 31 Yu H., Jiang W, Du H, Xing Y, Bai G, Zhang Y, et al. Involvement of the Akt/NF-κB
579 pathways in the HTNV-mediated increase of IL-6, CCL5, ICAM-1, and VCAM-1 in HUVECs.
580 *PloS One* 2014;9:e93810.
581
- 582 32 Niikura M, Maeda A, Ikegami T, Saijo M, Kurane I, Morikawa S. Modification of
583 endothelial cell functions by Hantaan virus infection: prolonged hyper-permeability induced by
584 TNF-alpha of hantaan virus-infected endothelial cell monolayers. *Arch Virol.* 2004;149, 1279–
585 1292.
586
- 587 33 Alsaffar H, Martino N, Garrett JP, Adam AP. Interleukin-6 promotes a sustained loss of
588 endothelial barrier function via Janus kinase-mediated STAT3 phosphorylation and de novo
589 protein synthesis. *Am J Physiol Cell Physiol.* 2018;314:C589–C602.
590
- 591 34 Jiang H., Wang PZ, Zhang Y, Xu Z, Sun L, Wang LM, et al. Hantaan virus induces toll-
592 like receptor 4 expression, leading to enhanced production of beta interferon, interleukin-6 and
593 tumor necrosis factor-alpha. *Virology* 2008;380:52–59.
594
- 595 35 Khaiboullina SF, Morzunov SP, St Jeor SC, Rizvanov AA, Lombardi VC. Hantavirus
596 infection suppresses thrombospondin-1 expression in cultured endothelial cells in a strain-specific
597 manner. *Front Microbiol.* 2016;7:1077.
598
- 599 36 Montgomery A, Tam F, Gursche C, Cheneval C, Besler K, Enns W, et al. Overlapping and
600 distinct biological effects of IL-6 classic and trans-signaling in vascular endothelial cells. *Am J*
601 *Physiol Cell Physiol.* 2021;320:C554–C565.
602
- 603 37 Connolly-Andersen A-M, Thunberg T, Ahlm C. Endothelial activation and repair during
604 hantavirus infection: association with disease outcome. *Open Forum Infect Dis.* 2014;1:ofu027.

- 605 38 Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. Monocyte chemoattractant protein 1
606 acts as a T-lymphocyte chemoattractant. *Proc Natl Acad Sci USA*. 1994;91:3652–3656.
607
- 608 39 Gschwandtner M, Derler R, Midwood KS. More than just attractive: How CCL2 influences
609 myeloid cell behavior beyond chemotaxis. *Front Immunol*. 2019;10:2759.
610
- 611 40 Lee CH, Zhang HH, Singh SP, Koo L, Kabat J, Tsang H, et al. C/EBP δ drives interactions
612 between human MAIT cells and endothelial cells that are important for extravasation. *eLife*
613 2018;7:e32532.
614
- 615 41 Lo C-W, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, et al., IL-6 trans-signaling
616 in formation and progression of malignant ascites in ovarian cancer. *Cancer Res*. 2011;71:424–
617 434.
618
- 619 42 Gorbunova E., Gavrilovskaya IN, Mackow ER. Pathogenic hantaviruses Andes virus and
620 Hantaan virus induce adherens junction disassembly by directing vascular endothelial cadherin
621 internalization in human endothelial cells. *J Virol*. 2010;84:7405–7411.
622
- 623 43 Shrivastava-Ranjan P. Rollin PE, Spiropoulou CF. Andes virus disrupts the endothelial cell
624 barrier by induction of vascular endothelial growth factor and downregulation of VE-cadherin. *J*
625 *Virol*. 2010;84:11227–11234.
626
- 627 44 Aparicio-Siegmund S, Garbers Y, Flynn CM, Waetzig GH, Gouni-Berthold I, Krone W, et
628 al. The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes.
629 *Am J Physiol Endocrinol Metab*. 2019;317:E411–E420.
630
- 631 45 Schuett H, Oestreich R, Waetzig GH, Annema W, Luchtefeld M, Hillmer A, et al.
632 Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. *Arterioscler*
633 *Thromb Vasc Biol*. 2012;32:281–290.
634
- 635 46 Cui Y, Dai W, Li Y. Circulating levels of sgp130 and sex hormones in male patients with
636 coronary atherosclerotic disease. *Atherosclerosis* 2017;266:151–157.
637
- 638 47 Korotaeva AA, SamoiloVA EV, Chepurnova DA, Zhitareva IV, Shuvalova YA, Prokazova
639 NV. Soluble glycoprotein 130 is inversely related to severity of coronary atherosclerosis.
640 *Biomarkers* 2018;23:527–532.
641
- 642 48 Moreno Velásquez I, Golabkesh Z, Källberg H, Leander K, de Faire U, Gigante B.
643 Circulating levels of interleukin 6 soluble receptor and its natural antagonist, sgp130, and the risk
644 of myocardial infarction. *Atherosclerosis* 2015;240:477–481.
645
- 646 49 Vandoorne K, Addadi Y, Neeman M. Visualizing vascular permeability and lymphatic
647 drainage using labeled serum albumin. *Angiogenesis* 2010;13:75–85.
648

- 649 50 Wu MA, Fossali T, Pandolfi L, Carsana L, Ottolina D, Frangipane V, et al.
650 Hypoalbuminemia in COVID-19: assessing the hypothesis for underlying pulmonary capillary
651 leakage. *J Intern Med*. 2021;289:861–872.
652
- 653 51 Nolte KB, Feddersen RM, Foucar K, Zaki SR, Koster FT, Madar D, et al. Hantavirus
654 pulmonary syndrome in the United States: a pathological description of a disease caused by a new
655 agent. *Hum Pathol*. 1995;26:110–120.
656
- 657 52 Boroja M., Barrie JR, Raymond GS. Radiographic findings in 20 patients with hantavirus
658 pulmonary syndrome correlated with clinical outcome. *Am J Roentgenol*. 2002;178:159–163.
659
- 660 53 Duchin JS, Koster FT, Peters CJ, Simpson GL, Tempest B, Zaki SR, et al. Hantavirus
661 pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. *N Engl
662 J Med*. 1994;330:949–955.
663
- 664 54 Tanaka T, Narazaki M, Ogata A, Kishimoto T, A new era for the treatment of inflammatory
665 autoimmune diseases by interleukin-6 blockade strategy. *Semin Immunol*. 2014;26:88–96.
666
- 667 55 The REMAP-CAP Investigators, Interleukin-6 receptor antagonists in critically ill patients
668 with Covid-19. *N Engl J Med*. 2021;384:1491–1502.

669 **Table 1. Patient characteristics and clinical data.**

Parameter	Controls	HFRS patients	
		Acute phase	Conv. phase
No. of patients	20	28	
Gender (female/male)	7/13	13/15	
Age (years), mean (range)	50 (37-63)	49 (18-78)	
Days post symptoms debut, median (range)	NA	5 (2-7)	63 (42-494)
WBC count ($\times 10^9/L$), mean \pm SD*	n.d.	8.9 \pm 5.3	7.1 \pm 2.5
Platelet count ($\times 10^9/L$), mean \pm SD [#]	n.d.	91 \pm 49	276 \pm 46
Serum creatinine ($\mu\text{mol/L}$), mean \pm SD [§]	n.d.	204 \pm 150	87 \pm 41
CRP (mg/L), mean \pm SD [€]	n.d.	75 \pm 47 ^a	4 \pm 3 ^b
Serum albumin (g/L), mean \pm SD [†]	n.d.	32 \pm 5.8 ^c	42 \pm 3.5 ^d
Intravenous fluid, no. of patients (%)	NA	19/28 (68)	NA
Platelet transfusion, no. of patients (%)	NA	3/28 (10)	NA
Oxygen treatment, no. of patients (%)	NA	8/28 (29)	NA
Severe bleeding, no. of patients (%)	NA	4/28 (14)	NA
Thrombosis, no. of patients (%)	NA	4/28 (14)	NA

670
671 Abbreviations: HFRS, hemorrhagic fever with renal syndrome; NA, not applicable; WBC, white
672 blood cell; n.d., not done; CRP, C-reactive protein.

673 *WBC; normal range, 3.5-8.8 $\times 10^9/L$.

674 [#]Platelet count; normal range, 165-387 $\times 10^9/L$ for women, 145-348 $\times 10^9/L$ for men.

675 [§]Serum creatinine; reference value <90 $\mu\text{mol/L}$ for women, <105 $\mu\text{mol/L}$ for men.

676 [€]CRP; reference value <3 mg/L.

677 [†]Serum albumin; normal range 34-54 g/L.

678 ^an=26.

679 ^bn=25.

680 ^cn=13.

681 ^dn=9.

682